HIGHBuilt-inGeographic
manufacturing outside the U.S.
“10-K Item 1A: 'We manufacture substantially all of our products outside the U.S. and sell a significant portion of our products outside the U.S.'”
RMD · Concentration risk · 10-K extracted
ResMed (RMD) concentration risks
Updated
The most significant concentration ResMed discloses is manufacturing outside the U.S., classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: ResMed’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 2 disclosed concentrations
HIGH1
MEDIUM1
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
MEDIUMBuilt-inGeographic
37%
Rest of World regions
“10-K Item 1A: 'Sales in Rest of World regions accounted for approximately 37% and 36% of our net revenues in the years ended June 30, 2026 and June 30, 2025, respectively.'”
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-10-18ResMed's concentrations are geographic and structural. The company manufactures substantially all of its products outside the U.S. and sells a significant portion of its products outside the U.S., a high-share exposure that leaves both its cost base and a large part of its demand exposed to foreign operating conditions, trade policy and currency. The sales side is quantified: Rest of World regions accounted for approximately 37% and 36% of net revenues in the years ended June 30, 2026 and June 30, 2025, respectively. That is a medium-share exposure and has been steady across the two periods rather than shifting sharply. Taken together, the two items describe a single theme seen from two angles, where the products are made and where they are sold. They are structural features of a global medical-device model, not counterparty-specific dependencies, and they partly offset each other, since foreign sales provide a natural counterweight to foreign cost exposure. The manufacturing footprint is the more concentrated of the pair and the one that could most plausibly move the verdict in a trade or supply disruption.
For the engine’s reasoning on RMD’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Medical Instruments & Supplies
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| ATRC | AtriCure, Inc. | 1 | 1 | 1 | 3 |
| ATR | AptarGroup, Inc. | 1 | 1 | 0 | 2 |
| RMD● | ResMed Inc. | 1 | 1 | 0 | 2 |
| ALGN | Align Technology, Inc. | 1 | 0 | 0 | 1 |
| AVTR | Avantor, Inc. | 1 | 0 | 0 | 1 |
| ANGO | AngioDynamics, Inc. | 0 | 1 | 0 | 1 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.